With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …

Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …

Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …

Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …

Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …

Identifying molecular residual disease (MRD) after treatment of localized lung cancer could
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …

Radiation-induced lung injury (RILI) encompasses any lung toxicity induced by radiation
therapy (RT) and manifests acutely as radiation pneumonitis and chronically as radiation …